Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. IBM
5. META
6. MU
7. ACN
8. NVDA
9. FDX
10. BLZE

Go back to Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

September 9, 2024 7:05 AM EDT

Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted)

Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration

Distinct drug properties support potential to be a leading GLP-1R agonist... More